SC1 - Health, demographic change and wellbeing

About this programme

Responding to this challenge, research and innovation (R&I) under Horizon 2020 is an investment in better health for all. It aims to keep older people active and independent for longer and supports the development of new, safer and more effective interventions. R&I under Horizon 2020 also contributes to the sustainability of health and care systems.

Research & Innovation supported by this call will:

  • improve our understanding of the causes and mechanisms underlying health, healthy ageing and disease;
  • improve our ability to monitor health and to prevent, detect, treat and manage disease;
  • support older persons to remain active and healthy;
  • and test and demonstrate new models and tools for health and care delivery.
Click to read more 
Hide text 

Your NCP contact for this programme

Image of Lieve Apers

Lieve Apers

lieve.apers@vlaio.be

+32 497 59 33 58

Your PC contact for this programme

Find the contact info on the site of WEWIS

The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.

The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.

Latest news

Upcoming events

No events that are specifically related to SC1 - Health, demographic change and wellbeing were found. Check the full calendar.

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.